Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221232 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™
A Phase 2 study, sponsored by Zurex Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02221232: Clinical Trial Phase 2 study, sponsored by Zurex Pharma.
NCT02221232 is a Phase 2 study that was terminated before completion, run by Zurex Pharma. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02221232, a Phase 2 study, was terminated before completion, sponsored by Zurex Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to evaluate antimicrobial properties of a single test product, a vehicle product and a reference product applied in two different areas when used as a patient preoperative skin preparation.
Primary Outcome
Antimicrobial efficacy will be evaluated based upon calculation of mean log10 reductions from baseline populations by subtracting the log10 number of viable microorganisms recovered at each post-product application sample from the log10 number of viable microorganisms recovered in the baseline samples. The performance criteria are mean reductions in microbial flora of ≥2 log10 per square cm on skin of the abdomen and ≥3 log10 per square cm on skin of the inguen.
Interventions
- DRUG ZuraPrep
- DRUG ZuraPrep Vehicle
- DRUG Chloraprep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Why NCT02221232 stopped before completion
NCT02221232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which ZuraPrep is the first listed.
NCT02221232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02221232 about?
NCT02221232 is a clinical study titled "Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™". The purpose of this pilot study is to evaluate antimicrobial properties of a single test product, a vehicle product and a reference product applied in two different areas when used as a patient preoperative skin preparation.
What is the current status of trial NCT02221232?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02221232?
The interventions under investigation include: ZuraPrep (DRUG), ZuraPrep Vehicle (DRUG), Chloraprep (DRUG).
Who is sponsoring clinical trial NCT02221232?
This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02221232's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia